A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B
10.1001/archinte.166.1.49
Saved in:
Main Authors: | Lim, S.G., Ng, T.M., Guan, R., Kung, N., Krastev, Z., Volfova, M., Husa, P., Lee, S.S., Chan, S., Shiffman, M.L., Washington, M.K., Rigney, A., Anderson, J., Mondou, E., Snow, A., Sorbel, J., Rousseau, F. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
2011
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/26688 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B
by: Lim, S.G., et al.
Published: (2011) -
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial
by: Kathleen Mulligan, et al.
Published: (2018) -
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial
by: Kathleen Mulligan, et al.
Published: (2018) -
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
by: Avihingsanon A.
Published: (2023) -
The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B
by: Solomon M., et al.
Published: (2017)